GENERIC NAME: repagIinide

BRAND NAME: Prandin
DRUG CLASS AND MECHANISM: Repaglinide is an oral medication for lowering blood
sugar (glucose) in individuals with diabetes. Ìt is in a class of drugs for
treating diabetes type 2 called meglitinides and is chemically unlike other anti-diabetic
medication.
Approximately 90% of patients with diabetes have type 2 or non-insulin dependent
diabetes mellitus. (Type 2 diabetes usually occurs in adulthood, and is associated
with obesity and a strong family history of diabetes.) Glucose intolerance in diabetes
type ÌÌ is caused by reduced insulin secretion from the pancreas after meals and
resistance of the body's cells to insulin's effect which is to stimulate the cells to remove
glucose from the blood. This leads to high levels of blood glucose.
Like Sulfonylureas, for example, glyburide (Diabeta; Glynase;
Micronase),glipizide (Glucotrol), glimepiride (Amaryl), tolbutamide (Orinase),
andtolazamide (Tolinase), repaglinide stimulates cells in the pancreas to produce
insulin. Glyburide may be more potent than repaglinide at increasing insulin release in
persons with low or high blood glucose levels, whereas repaglinide may be more potent
in persons with moderate blood glucose levels. Repaglinide is unusual in that it has a
rapid onset of action and a short duration of action. When taken just prior to meals, it
promotes the release of insulin that normally occurs with meals and is responsible for
preventing blood glucose levels from becoming high. Ìt has been shown to
lower hemoglobin A1c levels by 1.6% to 1.9%. (Hemoglobin A1c is a blood test which
measures the effectiveness of a drug in controlling high blood glucose levels. The lower
the hemoglobin A1c, the better the control.) Repaglinide was approved by the FDA in
1997.

Sign up to vote on this title
UsefulNot useful